Friday, October 16, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 6, 2026

Stock market today: Dow soars 1,000 points, leading S&P 500, Nasdaq higher as Wall Street rebounds from rout

View original at finance.yahoo.com
Stock market today: Dow soars 1,000 points, leading S&P 500, Nasdaq higher as Wall Street rebounds from rout US stocks jumped on Friday, set to rebound from a weeklong tech bruising as Wall Street reassessed worries about the impact of AI disruption and the risks of hefty Big Tech spending…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Fed signals higher bar for interest rate cuts, sees rates in 'neutral range'

    80% confidence

  • The FDA will take swift action against companies mass-marketing illegal copycat drugs

    80% confidence

  • Investors will likely start once again giving credit to the companies that are capturing all the profits from Big Tech's AI investments

    80% confidence

  • In a few short years Caterpillar has become the ultimate story stock, touching several big market themes including AI/Power, infrastructure, and critical minerals

    80% confidence

  • Medical costs have risen across government-backed health plans

    80% confidence

  • Novo Nordisk will take legal and regulatory action to protect patients, intellectual property and the integrity of the US drug approval framework

    80% confidence

  • It's all going to Nvidia - referring to Big Tech's $600+ billion AI capex spending

    80% confidence

  • Amazon forecast for operating income fell short of expectations

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Stock market today: Dow soars 1,000 points, leading S&P 500, Nasdaq higher as Wall Street rebounds from rout — Source | Via News | Finance Via News